Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 73.4% in October

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 2,410,000 shares, a growth of 73.4% from the October 15th total of 1,390,000 shares. Based on an average daily trading volume, of 525,700 shares, the days-to-cover ratio is presently 4.6 days.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ACRS shares. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 7th.

Aclaris Therapeutics Trading Down 10.7 %

Shares of NASDAQ ACRS opened at $2.18 on Friday. The stock has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $1.29. Aclaris Therapeutics has a 12 month low of $0.67 and a 12 month high of $2.72. The company has a market cap of $155.72 million, a price-to-earnings ratio of -4.19 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. On average, sell-side analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ACRS. SG Americas Securities LLC increased its holdings in Aclaris Therapeutics by 69.5% in the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares in the last quarter. Trium Capital LLP increased its stake in shares of Aclaris Therapeutics by 1.1% in the third quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock valued at $2,200,000 after buying an additional 20,940 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 23,747 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Aclaris Therapeutics in the 1st quarter valued at approximately $39,000. Finally, Russell Investments Group Ltd. boosted its position in Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after buying an additional 61,602 shares during the period. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.